ACEIs and ARBs are the preferred agents for treatment of high blood pressure in people with diabetes and urine albumin to creatinine ratio (UACR) ≥ 30 or eGFR < 60 mL/min/1.73 m2, as these protect against kidney disease progression [49]. The gene discussed is ALB; the disease is hypertensive disorder.